SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Pacific Biosciences of California, Inc. Announces Second Quarter 2019 Financial Results
[August 06, 2019]

Pacific Biosciences of California, Inc. Announces Second Quarter 2019 Financial Results


MENLO PARK, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2019.

On April 24, 2019, the Company announced the commercial launch of the Sequel II System and the Single Molecule, Real-Time (SMRT®) Cell 8M chip, and began shipping Sequel II Systems to customers beyond the five early access sites.  As of June 30, 2019, the Company had installed a total of 41 Sequel II Systems, which includes a number of sites with multiple systems installed.

On November 1, 2018, the Company entered into an Agreement and Plan of Merger with Illumina, Inc. (“Illumina”) and FC Ops Corp., a wholly-owned subsidiary of Illumina (the “Merger Agreement”) pursuant to which Illumina will acquire the Company for $8.00 per share of the Company’s common stock in an all-cash transaction and FC Ops Corp. will be merged with and into the Company (the “Merger”), with the Company surviving the Merger and becoming a wholly-owned subsidiary of Illumina. Completion of the transaction is subject to terms and conditions set forth in the Merger Agreement, including expiration or termination of any waiting periods applicable to the consummation of the Merger under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and clearance under the antitrust laws of certain non-U.S. jurisdictions. The Merger has been notified to the United States Federal Trade Commission (“FTC”) and to the Competition and Markets Authority of the United Kingdom (“CMA”) and is under review by both the FTC and the CMA. The Company and Illumina will continue to work cooperatively with the FTC and the CMA. The Company and Illumina expect the Merger to be completed in the fourth quarter of 2019, at which time the Company will become a wholly owned subsidiary of Illumina and will cease to be a publicly traded company. For the three and six months ended June 30, 2019, the Company recognized approximately $3.8 million and $9.3 million, respectively, in operating expenses in connection with the Merger.

No Conference Call

Given the pending Merger with Illumina, management will not be hosting a conference call to discuss its financial results for the second quarter ended June 30, 2019 and does not expect to do so for future quarters.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel SMRT® Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development and commercialization of products, future uses, quality or performance of, or benefits of using, products or technologies, the commercial launch of the Sequel II System, the expected availability of SMRT® Cell 8M chips, the performance of the Sequel II System, the Merger Agreement and Merger including the expected timing of the completion of the Merger and whether the Merger will be consummated, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

The condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in the Company’s Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission.

Contact:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com

 
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(amounts in thousands, except per share amounts)
            
 Three Months Ended June 30, Six Months Ended June 30,
 2019 2018 2019 2018
Revenue:           
Product revenue$21,250  $18,485  $34,707  $34,767 
Service and other revenue 3,371   3,093   6,339   6,173 
Total revenue 24,621   21,578   41,046   40,940 
Cost of Revenue:           
Cost of product revenue 11,980   9,858   20,598   18,877 
Cost of service and other revenue 3,028   2,858   5,718   5,905 
Total cost of revenue 15,008   12,716   26,316   24,782 
Gross profit 9,613   8,862   14,730   16,158 
Operating Expense:           
Research and development 14,910   15,664   30,395   31,975 
Sales, general and administrative 19,083   14,943   38,849   29,877 
Total operating expense 33,993   30,607   69,244   61,852 
Operating loss (24,380)  (21,745)  (54,514)  (45,694)
Interest expense (644)  (598)  (1,269)  (1,179)
Other income (expense), net 428   (197)  863   154 
Net loss$(24,596) $(22,540) $(54,920) $(46,719)
Basic and diluted net loss per share$(0.16) $(0.17) $(0.36) $(0.37)
Shares used in computing basic and diluted net loss per share 152,776   131,882   152,029   127,847 
                




 
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(amounts in thousands)
        
 June 30,  December 31,
 2019 2018
Assets   
Cash and investments$66,844  $102,354 
Accounts receivable 12,123   8,595 
Inventory 17,404   17,878 
Prepaid and other current assets 2,538   2,832 
Property and equipment, net 33,457   34,073 
Operating lease right-of-use assets, net 34,175    
Long-term restricted cash 4,000   4,500 
Other long-term assets 41   43 
Total Assets$170,582  $170,275 
        
Liabilities and Stockholders' Equity       
Accounts payable$8,011  $6,736 
Accrued expenses 14,107   12,823 
Deferred service revenue 8,161   7,427 
Operating lease liabilities 47,552    
Notes payable 15,233   14,659 
Deferred rent    13,765 
Other liabilities 1,764   788 
Financing derivative    16 
Stockholders' equity 75,754   114,061 
Total Liabilities and Stockholders' Equity$170,582  $170,275 
        

Primary Logo



[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy